Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + Cemiplimab in First-Line Advanced NSCLC with PD-L1 ≥50%
NCT05785767Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of fianlimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective Response Rate at 136 weeks. Started Jun 2023; status: active, not recruiting.
02
Drugs
fianlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05785767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785767.